Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ICUI
stocks logo

ICUI

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
543.33M
-8.91%
--
--
511.68M
-13.15%
--
--
540.60M
-14.16%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for ICU Medical, Inc. (ICUI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.37%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-4.37%
In Past 3 Month
3 Analyst Rating
up Image0
Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 189.00 USD with a low forecast of 187.00 USD and a high forecast of 191.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
up Image0
Current: 130.060
sliders
Low
187.00
Averages
189.00
High
191.00
up Image0
Current: 130.060
sliders
Low
187.00
Averages
189.00
High
191.00
Raymond James
Strong Buy
downgrade
$197 -> $187
2025-05-09
Reason
Raymond James
Price Target
$197 -> $187
2025-05-09
downgrade
Strong Buy
Reason
Raymond James lowered the firm's price target on ICU Medical to $187 from $197 and keeps a Strong Buy rating on the shares. ICU Medical's Q1 results were well ahead of consensus, highlighted by 10% revenue growth, the analyst tells investors in a research note. While comps will get tougher, ICU's cadence of innovation on the pump side lends more confidence in the top-line growth profile over the next couple of years, the firm says.
Keybanc
Tim Rezvan
Buy
Maintains
$209 → $191
2025-04-21
Reason
Keybanc
Tim Rezvan
Price Target
$209 → $191
2025-04-21
Maintains
Buy
Reason
KeyBanc analyst Brett Fishbin lowered the firm's price target on ICU Medical to $191 from $209 and keeps an Overweight rating on the shares. The firm believes underlying MedTech trends remain mostly positive heading into Q1 earnings season, but is lowering several price targets to reflect macro concerns around the potential impact of tariffs as well as an increased risk of recession.
Needham
Mike Matson
Hold
Reiterates
n/a
2025-04-08
Reason
Needham
Mike Matson
Price Target
n/a
2025-04-08
Reiterates
Hold
Reason
Jefferies
Michael Toomey
Hold
to
Strong Buy
Upgrades
$200
2024-12-11
Reason
Jefferies
Michael Toomey
Price Target
$200
2024-12-11
Upgrades
Hold
to
Strong Buy
Reason
Jefferies upgraded ICU Medical to Buy from Hold with an unchanged price target of $200. The firm continues to like ICU's core infusion pump marker, which it says is supported by a "healthy" utilization environment with share gain and margin expansion opportunities. The pullback in the shares appears to bake in tariff risk, and the current valuation based "appears compelling relative to the company's growth profile at twice peers," the analyst tells investors in a research note.
Needham
Mike Matson
Hold
Reiterates
n/a
2024-11-13
Reason
Needham
Mike Matson
Price Target
n/a
2024-11-13
Reiterates
Hold
Reason
Keybanc
Brett Fishbin
Buy
Maintains
$198 → $209
2024-11-13
Reason
Keybanc
Brett Fishbin
Price Target
$198 → $209
2024-11-13
Maintains
Buy
Reason
KeyBanc raised the firm's price target on ICU Medical to $209 from $198 on higher multiple, while keeping an Overweight rating on the shares. The firm was broadly encouraged by a continuation of improved underlying momentum, and views the initial details around its IV Solutions JV agreement favorably.
See All Ratings

Valuation Metrics

The current forward P/E ratio for ICU Medical Inc (ICUI.O) is -62.43, compared to its 5-year average forward P/E of 4.94. For a more detailed relative valuation and DCF analysis to assess ICU Medical Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
4.94
Current PE
-62.43
Overvalued PE
207.63
Undervalued PE
-197.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
13.47
Current EV/EBITDA
11.46
Overvalued EV/EBITDA
15.28
Undervalued EV/EBITDA
11.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.07
Current PS
1.40
Overvalued PS
2.90
Undervalued PS
1.23

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 3506.02% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased100%over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 3506.02% over the last month.
Sold
Bought

ICUI News & Events

Events Timeline

(ET)
2025-05-08
16:49:55
ICU Medical reports Q1 adjusted EPS $1.72, consensus $1.28
select
2025-04-07 (ET)
2025-04-07
08:05:15
ICU Medical announces FDA 510(k) clearance for Plum Solo, Plum Duo pumps
select
2025-02-27 (ET)
2025-02-27
16:38:21
ICU Medical sees FY25 EPS $6.55-$7.25, consensus $7.13
select
Sign Up For More Events
Sign Up For More Events

News

Preview
5.0
07-25Yahoo Finance
Chest Drainage Catheters Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Leading Players - BD, Teleflex, Cook, ICU Medical, and Redax

  • Market Growth Forecast: The global chest drainage catheters market is expected to grow at a CAGR of 4.78% from 2025 to 2032, driven by the rising prevalence of chronic diseases and advancements in minimally invasive procedures, particularly in North America.

  • Key Market Dynamics: Increasing cases of lung cancer and cardiovascular diseases are boosting demand for chest drainage catheters, while innovations in catheter technology and challenges like regulatory requirements shape the market landscape.

Preview
7.0
05-20PRnewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ICU Medical, Inc. - ICUI

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud claims against ICU Medical, Inc. following a warning letter from the FDA regarding unauthorized changes to its infusion pump products, which raised safety concerns.

  • Stock Impact: Following the FDA's warning, ICU Medical's stock price dropped by 4.42%, closing at $130.68 per share on April 22, 2025.

Preview
7.0
05-14Globenewswire
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

  • Investigation of Companies: Bragar Eagel & Squire, P.C. is investigating potential claims against Organon & Co., Aldeyra Therapeutics, Landstar System, and ICU Medical for possible violations of federal securities laws and unlawful business practices.

  • Recent Company Issues: Organon reported a significant revenue decline and cut its dividend, Aldeyra faced FDA concerns over a drug application, Landstar identified supply chain fraud affecting earnings, and ICU received an FDA warning regarding unauthorized changes to its infusion pumps.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ICU Medical Inc (ICUI) stock price today?

The current price of ICUI is 130.06 USD — it has increased 2.09 % in the last trading day.

arrow icon

What is ICU Medical Inc (ICUI)'s business?

ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.

arrow icon

What is the price predicton of ICUI Stock?

Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 189.00 USD with a low forecast of 187.00 USD and a high forecast of 191.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ICU Medical Inc (ICUI)'s revenue for the last quarter?

ICU Medical Inc revenue for the last quarter amounts to 604.70M USD, increased 6.71 % YoY.

arrow icon

What is ICU Medical Inc (ICUI)'s earnings per share (EPS) for the last quarter?

ICU Medical Inc. EPS for the last quarter amounts to -0.63 USD, decreased -61.35 % YoY.

arrow icon

What changes have occurred in the market's expectations for ICU Medical Inc (ICUI)'s fundamentals?

The market is revising No Change the revenue expectations for ICU Medical, Inc. (ICUI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.37%.
arrow icon

How many employees does ICU Medical Inc (ICUI). have?

ICU Medical Inc (ICUI) has 15000 emplpoyees as of August 05 2025.

arrow icon

What is ICU Medical Inc (ICUI) market cap?

Today ICUI has the market capitalization of 3.20B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free